News

Nivolumab added to AVD chemotherapy expected to become new standard for initial treatment for advanced stage disease in adolescents and adults, based on trial data to be presented at 2023 ASCO Annual Meeting plenary session

Results of SWOG S1929 trial show patients with small-cell lung cancer with SLFN11 expression can benefit from PARP inhibitor added to immune checkpoint blockade

Changes in RECIST tumor measures correlate linearly with survival in patients treated with checkpoint inhibitors

S1714 results at ASCO 2023: Taxane-induced peripheral neuropathy in breast cancer: frequent, clinically significant, and worse with paclitaxel

Extended lymph node removal does not benefit patients with clinically localized muscle-invasive bladder cancer

SWOG researchers have also contributed to an additional 11 abstracts on studies led by other groups.

Drs. Dawn Hershman and Primo Lara elected group co-chairs-elect of SWOG Cancer Research Network

SWOG researchers report results in rare gynecologic cancers from S1609 DART immunotherapy trial

SWOG S1512 trial sees high response rate to pembrolizumab in patients with unresectable desmoplastic melanoma